Antimicrobial ReportsFrequency of Dosing of Cephalexin for Oral Step-Down Therapy of Pediatric Osteoarticular Infections Caused by Methicillin-Sensitive Staphylococcus AureusRamchandar, Nanda MD, MPH; Arnold, John MD; Cannavino, Chris MD; Bradley, John S. MDAuthor Information From the Rady Children’s Hospital, University of California, San Diego, CA. Accepted for publication February 29, 2020. The authors have no funding or conflicts of interest to disclose. Address for correspondence: John S. Bradley, MD, Department of Pediatrics, University of California, San Diego, CA. E-mail: email@example.com. The Pediatric Infectious Disease Journal: June 2020 - Volume 39 - Issue 6 - p 523-525 doi: 10.1097/INF.0000000000002661 Buy Metrics Abstract Osteoarticular infections are one of the more common invasive bacterial infections encountered in children. There exist significant practice variations in both the diagnosis and treatment of such infections. However, the practice of transitioning from parenteral therapy to oral antibiotics has been well validated by several studies. For methicillin-sensitive Staphylococcus aureus (MSSA), cephalexin is often recommended. Prospective, controlled data regarding optimal dosing of cephalexin in pediatric osteomyelitis are not available. We sought to review our retrospective, uncontrolled data on four times daily (QID) versus three times daily (TID) dosing of cephalexin for pediatric osteoarticular infections. Children ≥1 month to <18 years of age admitted to Rady Children’s Hospital-San Diego with a diagnosis of osteomyelitis or septic arthritis between January 1, 2002, and November 30, 2007, were identified and previously reported. Only patients with culture-positive MSSA infections are included in this report. Demographic and clinical data were manually extracted from the electronic medical record. Fifty-nine patients were treated with cephalexin and had records available for review through our electronic medical record. Thirty-eight patients (64.4%) were treated QID, and 21 patients (35.6%) were treated TID. Clinical cure was achieved in all patients with only one adverse event occurring in the QID group. In this retrospective chart review of children with osteoarticular infections caused by MSSA treated with cephalexin, similar clinical outcomes were found with QID versus TID dosing. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.